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Abstract: In recent years, the study of genomic alterations and protein expression involved in the
pathways of breast cancer carcinogenesis has provided an increasing number of targets for drugs
development in the setting of metastatic breast cancer (i.e., trastuzumab, everolimus, palbociclib,
etc.) significantly improving the prognosis of this disease. These drugs target specific molecular
abnormalities that confer a survival advantage to cancer cells. On these bases, emerging evidence
from clinical trials provided increasing proof that the genetic landscape of any tumor may dictate its
sensitivity or resistance profile to specific agents and some studies have already showed that tumors
treated with therapies matched with their molecular alterations obtain higher objective response
rates and longer survival. Predictive molecular biomarkers may optimize the selection of effective
therapies, thus reducing treatment costs and side effects. This review offers an overview of the main
molecular pathways involved in breast carcinogenesis, the targeted therapies developed to inhibit
these pathways, the principal mechanisms of resistance and, finally, the molecular biomarkers that,
to date, are demonstrated in clinical trials to predict response/resistance to targeted treatments in
metastatic breast cancer.
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1. Introduction
Breast cancer (BC) represents the most common cancer among women worldwide, with an
estimated incidence of 246,660 new cases (29% of all sites cancers) and 40,450 estimated deaths (14% of
all sites) in 2016 in the United States [1]. Despite the relevant progress in prevention, diagnosis,
and treatment of BC and the consequent improvement in overall survival, metastatic BC continues to
be an incurable disease with a median survival time of 18–24 months, depending on the extension of
the tumor and its histopathological and molecular profile [2–6].
At the molecular level, BC is a heterogeneous disease that develops and progresses from alterations
that take place in the genes that govern cell growth, proliferation and differentiation [7,8]. In the last
two decades, the increasing knowledge on genomic abnormalities associated with gain of function
or downstream signal activation involved in the BC evolution, allowed to find new therapeutic
approaches “tailored” on the molecular alteration identified. The revolutionary era of targeted therapy
shifted the classic paradigm of BC treatment from a “stratified oncology” based on pathological and
clinical parameters [9] to a “personalized medicine” based on the match between the targeted drug and
the molecular alteration that confers to cancer cells a survival advantage [10]. Currently, an increasing
number of these molecularly targeted drugs is available for clinical practice or in the context of clinical
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trials and, nowadays, the main challenge remains the identification of predictive biomarkers for the
selection of the optimal treatment, in order to spare patients from the side effects associated with
treatment and to minimize the overall cost [11].
This review aims to reassume the main molecular pathways involved in BC carcinogenesis, the
targeted therapies developed to inhibit those pathways, the principal mechanisms of resistance and,
finally, the molecular biomarkers that, to date, have demonstrated to predict response/resistance to
targeted treatments.
2. Signaling Pathways Involved in Breast Cancer Carcinogenesis
A large body of evidence in literature has already pointed out that cancer is the result of subsequent
genetic mutations in somatic cells [12,13]. These mutations affect and activate a number of cellular
pathways, which are responsible for growth, proliferation and differentiation in BC cells [14,15].
2.1. Estrogen Signaling Pathway (Figure 1)
Steroid hormones contribute to carcinogenesis in BC acting on cell growth, development,
differentiation, and homeostasis. Estrogens activate both nuclear estrogen receptors (ERα and ERβ,
genomic pathway) and membrane estrogen receptors (mER, non-genomic pathway) [16]. In the
genomic pathways, ligand-activated nuclear ER dimerizes and translocates in the nucleus where it
binds to DNA to regulate the activity of different genes. On the other hand, in the non-genomic
pathway, the mER activates a variety of signal transduction pathways, including the MAPK pathway
and the PI3K/AKT/mTOR pathway [17].
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JAK/STAT pathway. ER: estrogen receptor, RAS: rat sarcoma viral oncogene homolog, B-RAF: murine 
sarcoma viral oncogene homolog, MEK1/2: MAPK/Erk kinase 1/2, ERK1/2: extracellular-signal-
regulated kinase 1/2, SRC: rous sarcoma, RTKs: receptor tyrosine kinases, JAK: Janus kinase, STAT: 
Signal Transducer and Activator of Transcription, PI3K: Phosphoinositide 3-kinase, PTEN: 
Phosphatase and tensin homolog, AKT: protein kinase B, NFκB: nuclear factor κ-light-chain-enhancer 
of activated B cells, GSK3A/B: Glycogen synthase kinase-3 α/β, mTORC1/2: mammalian target of 
rapamycin complex 1/2, PIP: phosphatidylinositol phosphate, P: phosphorylated. Solid arrow: 
activation. Dashed arrow: activation of nuclear transcription factors. T-bar: inhibition. 
Figure 1. The crosstalking network of signaling pathways involved in breast cancer development
and progression: estrogen receptor (ER) signaling pathway, receptor tyrosine kinase (RTK)
pathway, PIK3/AKT/mTOR pathway, MAPK signaling pathway, angiogenic pathway, SRC pathway
and JAK/STAT pathway. ER: estrogen receptor, RAS: rat sarcoma viral oncogene homolog,
B-RAF: murine sarcoma viral oncogene homolog, MEK1/2: MAPK/Erk kinase 1/2, ERK1/2:
extracellu ar-signal-r gulated kin se 1/2, SRC: rous sarcoma, RTKs: recep or tyrosine kinases, JAK:
Janus kinase, STAT: Sig al Transducer and Activator of Transcription, PI3K: Phosphoinositide
3-kinase, PTEN: Phosphatase and tensin homolog, AKT: protein kinase B, NFκB: nuclear factor
κ-light-chain-enhancer of activated B cells, GSK3A/B: Glycogen synthase kinase-3 α/β, mTORC1/2:
mammalian target of rapamycin complex 1/2, PIP: phosphatidylinositol phosphate, P: phosphorylated.
Solid arrow: activation. Dashed arrow: activation of nuclear transcription factors. T-bar: inhibition.
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2.2. Epidermal Growth Factor Receptors (HER) Family (Figure 1)
The epidermal growth factor receptor (HER) family includes four different receptors: erbB1
(HER1 or EGFR), erbB2 (HER2), erbB3 (HER3), and erbB4 (HER4). This family of tyrosine kinase
receptors regulates several biological processes and is particularly involved in cell proliferation control,
differentiation, and survival [18]. A high expression of HER2 has been detected in 20% to 30% of
human breast carcinomas and correlates with a worse prognosis, since it is associated with higher
aggressiveness, shorter survival and high risk of endocrine therapy resistance [19]. In general, these
receptors are composed of an extracellular domain for ligand binding, a transmembrane segment, and
an intracellular domain with tyrosine kinase activity. The ligand binding causes conformational
changes in the receptor that allows dimerization (homo or hetero-dimerization) with the other
Epidermal Growth Factor Receptors and induces intracellular kinase domains phosphorylation
with the activation of “downstream” signaling pathways, including PI3K/AKT/mTOR, MAPK, and
JAK/STAT pathways, which promote proliferation and survival [20,21].
2.3. PI3K/AKT/mTOR Pathway (Figure 1)
PI3K/AKT/mTOR pathway is one of the main downstream pathways involved in cancer cell
proliferation and is activated by several receptor tyrosine kinases (RTKs), such as EGFR, IGF-1, FGFR,
MET, etc. PI3K represents a family of kinases classifiable into four main classes. Class I PI3Ks have a
catalytic subunit known as p110, with four isoforms: p110 α (encoded by PIK3CA), p110 β (encoded by
PIK3CB), p110 γ (encoded by PIK3CG), and p110 ∆ (encoded by PIK3CD) [22]. This first class of PI3Ks
is the one mainly involved in oncogenesis and has been the target for anti-cancer drug development.
The principal role of Class I PI3Ks is to phosphorylate the phoshatidyl-inositol(4,5)P2 (PIP2) to
phospha-tidilinositol(3,4,5)P3 (PIP3) [22]. After phosphorylation, PIP3 activates AKT. Activated
AKT recognizes a wide range of substrates, with their activating or inhibiting functions, such as
mTOR, NF-κB (nuclear factor of κB), MDM2 (a negative regulator of the oncosoppressor p53),
GSK3β (involved in cell cycle and glucose metabolism processes), etc. Therefore, activated AKT
mediates and regulates different biological processes, including growth independence, apoptosis and
proliferation [23,24].
PTEN (phosphatase and tensin homolog) is the negative regulator of PI3K/AKT/mTOR pathway
due to its dephosphorylating action. PTEN is a tumor suppressor with diverse functions, including
regulation of cell cycle, apoptosis and metastasis [25,26]. Mutations, or a reduced expression of
the PTEN gene, are associated with a wide variety of human tumors, including breast cancer [27].
Somatic mutations in all points of this pathway have been identified in BC. Particularly, mutations of
PIK3CA have been found in almost 30% of all sporadic BC [28] with a wide range of frequencies among
BC subtypes [29,30], whereas the frequency of PTEN loss is 30%–40% and the somatic intragenic PTEN
mutation frequency is <5% [31].
2.4. MAPK Signaling Pathway (Figure 1)
MAPK may lead to an uncontrolled cell cycle, resistance to apoptosis and to chemotherapy,
targeted therapies, and radiotherapy. The interaction between the RTKs (such as EGFR, PDGFR,
FGFR, etc.) and their ligands allows RAS (a family of small GTPases) to activate the protein kinase
activity of RAF, a serine/threonine kinase. RAF kinase, as a cascade, phosphorylates and activates
MEK (mitogen-activated protein kinase). MEK (MEK1 and MEK2) phosphorylates and activates
a mitogen-activated protein kinase, ERK (extracellular-signal-regulated kinase, also called MAPK),
which translocates into the nucleus where triggers several transcription factors that mediate expression
of oncogenes involved in proliferation and survival [32,33]. Overall, the most frequent somatic
mutations occurring in the MAPK cascade involve MAP3K1 (8%) and MAP2K4 (4%) [29].
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2.5. RB-E2F and p53 Pathways (Figure 2)
Cell cycle regulation can be perturbed by a wide range of mechanisms, including activation of
RB-E2F pathway and the p53 pathway. RB is one of the best-known oncosuppressors, responsible for
turning on or off the cell cycle [34]. One downstream consequence of RB activation is the inhibition of
E2F activity, which is important for the transcription of several genes that are required for progression
through the cell cycle. Particularly, E2F up-regulates the cyclin E gene and then, the cyclinE-CDK2
holoenzyme completes the phosphorylation and inactivation of RB [34–36]. In addition, the Cyclin D1,
upregulated by growth factors like EGF and estrogen, binds to CDK4/6 and partially phosphorylates
and inactivates RB [37]. In the p53 pathway, signals such as DNA damage, induce the tumor suppressor
ARF (alternate reading frame) to increase p53 levels by sequestering MDM2, which facilitates the
degradation and inactivation of p53. Simultaneously, the kinases ATM/ATR phosphorylate p53 directly
and through activation of CHK2 or CHK1. Among the p53 target genes are WAF1, an inhibitor of
cyclin-dependent protein kinases (CDKs) that, among other activities, causes cell-cycle arrest, and BAX,
which promotes apoptotic cell death. RB also regulates p53 activity through a trimeric p53-MDM2-RB
complex [38]. Overall, the most frequent somatic mutations occurring in these pathways involve TP53
(37%) and RB1 (2%) [29].
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2.6. Angiogenic Pathway (Figure 1) 
Tumor angiogenesis means the growth of new blood vessels, which are needed by the tumor in 
order to grow [39]. A huge number of molecules are involved in this process, some of them with a 
facilitating role (pro-angiogenic factors, such as the vascular endothelial growth factor, VEGF), others 
with an inhibiting role (anti-angiogenic factors). Activation of pro-angiogenic pathways in cancer 
cells is critical to cancer development [40]. Particularly, signal transduction induced by VEGF 
involves binding to tyrosine kinase receptors and results in endothelial cell proliferation, migration, 
and new vessel formation [41]. 
2.7. SRC Pathway (Figure 1) 
SRC (Rous Sarcoma) plays a critical role in the development and progression of many solid 
tumors and is also associated to the development of drug resistance [42]. SRC is the best-known 
member of a family of non-receptor cytoplasmatic tyrosine kinases (SFKs) involved in regulatory 
mechanisms of cell proliferation, growth, migration, and other neoplastic features. The SRC 
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2.7. SRC Pathway (Figure 1)
SRC (Rous Sarcoma) plays a critical role in the development and progression of many solid
tumors and is also associated to the development of drug resistance [42]. SRC is the best-known
member of a family of non-receptor cytoplasmatic tyrosine kinases (SFKs) involved in regulatory
mechanisms of cell proliferation, growth, migration, and other neoplastic features. The SRC activation
implicates a cascade of signaling pathways involved in oncogenesis, including PI3K/AKT/mTOR,
MAPK, and JAK/STAT [43].
2.8. HSP90 Mechanism of Action (Figure 3)
Under stressful conditions, the heat shock protein 90 (HSP90) molecular chaperone protects
oncoproteins (such as HER2, AKT, c-MYC, etc.) from degradation via the ubiquitin-proteasome
pathway. HSP90 is up-regulated in cancers, and this contributes to increase proliferation and decreased
apoptosis [44].
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Figure 3. HSP90 mechanism of action. The binding of a client protein to HSP90 requires the co-operation
of another chaperone (HSP70 and its co-factor HSP40). HOP mediates interaction between HSP70 and
HSP90. The exchange of ADP to ATP induces dissociation of HSP70 and its co-chaperones from the
complex that associate then with p23, forming a mature complex. Under stressful conditions, HSP90
protects oncoproteins (such as HER2, AKT, c-MYC, etc.) from degradation. HSP90: heat shock protein
90 kDa, HSP70: Heat-shock protein of 70-kDa, HSP40: heat shock protein 40 kDA, HOP: Hsp organizing
protein, ADP: Adenosine diphosphate, ATP: Adenosine triphosphate.
2.9. DNA Repair Mechanisms (Figure 4)
Several mechanisms are involved in the repair of DNA damage, which includes single-strand
breaks (SSBs) and double-strand breaks (DSBs). The SSB repair is accomplished by the base excision
repair (BER), the nucleic acid excision repair (NER) and the mismatch repair (MMR). Poly (ADP-ribose)
polymerase (PARP) is an enzyme involved in the BER. DSBs are corrected by the homologous
recombination (HR) and non-homologous end joining (NHEJ) systems. When a defect occurs in one
of the enzymes involved in HR, such as BRCA1 and BRCA2, the DSBs are repaired from error-prone
mechanisms, mostly NHEJ. The NHEJ activation results in increased risk of new chromosomal defects
and, thus, the development of cancer [45–48].
Int. J. Mol. Sci. 2017, 18, 85 6 of 24
Int. J. Mol. Sci. 2017, 18, 85  6 of 24 
 
 
Figure 4. DNA repair mechanisms and the role of PARP enzymes. PARP: Poly (ADP-ribose) polymerase. 
2.10. JAK/STAT Pathway (Figure 1) 
The interaction between the RTKs or the cytokine receptors and their ligands allows a 
conformational change in the JAK (Janus Kinase) inactive form, placed on the intracellular tails of the 
receptor. Active JAKs phosphorilate tyrosine residues of the intracytoplasmatic domain of the 
receptor itself, creating a binding domain for STAT protein (signal transducer and activator of 
transcription) that floats around in the cytoplasm. Phosphorylated STAT dimerizes with other STAT 
proteins and the activated dimer translocates into the nucleus and promotes transcription of genes 
involved in proliferation, differentiation, and apoptosis processes. Dysregulations in JAK-STAT 
functionality result in immune disorders and cancers [49]. 
2.11. Immune Pathway (Figure 5) 
Immune checkpoints are molecules in the immune system able to either turn up or down an 
immunogenic signal. Under physiologic conditions, a balance between co-inhibitory and co-
stimulatory signals maintains self-tolerance and immune homeostasis, protecting tissues from 
unnecessary damage. Tumor cells take advantage of these mechanisms to evade immune recognition 
by inhibiting the T cell signal. For their activation, T cells require two signals: the first signal is 
initiated by the T cell receptor (TCR) through antigen recognition, whereas the second one is 
mediated by the interaction between receptors and ligands of co-stimulatory and co-inhibitory 
signals (the immune checkpoints), which include CTLA-4 (cytotoxic T-lymphocyte-associated 
protein 4), PD-1 (programmed death 1), and PD-L1 (programmed death-ligand 1). In tumors, the 
expression of immune inhibitory molecules following oncogenic transformation results in the 
attenuation of immune reactions, immune resistance and, thus, cancer cell survival [50,51]. 
Figure 4. DNA repair mechanisms and the role of P P enzy es. P P: Poly (ADP-ribose) polymerase.
. . T Path ay (Figure 1)
i t t c t i r t t i li ll
f r atio al c ange i t e J (J s i se) i cti e f r , l ce t i tr ll l r t ils f t
ce tor. Active JAKs phosphorilate tyrosine residues of the in racytoplasmatic domain of the recep or
itself, crea ing a bindi domain for STAT protein (signal transducer and activator of transcription)
th t floats around in the cytoplasm. Phosphorylated STAT dim rizes with other STAT proteins and
the activate dimer tr nslocates into the nucleus and promotes transcription of genes inv lved in
proliferatio , differ ntiation, and apoptosis processes. Dysregulations in JAK-STAT fu ct onality result
in immune disorders and cancers [49].
2.11. I une Path ay (Figure 5)
I une checkpoints are olecules in the immune system able to either turn up or down
an immunogenic signal. Under physiologic conditions, a balance between co-inhibitory and
co-stimulatory signals maintains self-tolerance and immune homeostasis, protecting tissues fro
unnecessary da age. Tu or cells take advantage of these echanis s to evade i une recognition
by inhibiting the T cell signal. For their activation, T cells require two signals: the first signal
is initiated by the T cell receptor (TCR) through antigen recognition, hereas the second one is
ediated by the interaction between receptors and ligands of co-stimulatory and co-inhibitory signals
(the immune checkpoints), which include CTLA-4 (cytotoxic T-lymphocyte-associated protein 4),
PD-1 (programmed death 1), and PD-L1 (programmed death-ligand 1). In tumors, the expression of
immune inhibitory molecules following oncogenic transformation results in the attenuation of immune
reactions, immune resistance and, thus, cancer cell survival [50,51].
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3. argeted Therapies for the Treatment of Advanced Breast Cancer
The definition “targeted therapy” includes those treat ents that use substances able to identify
and tt ifi subtypes of cancer cells, wit the aim of minimizing damage to normal cells.
Som target d th rapies block the action of certain enzymes, proteins, or other molecules in olved in
the pathways of tumor growth and spread. Other types of targeted therapies enhance the immune
sy tem r sponse against cance cells or kill the cancer cells though the release of toxi substances.
Since t e early history of targeted therapy, with the adv t f endocrine treat ent more than 50 years
ago, significant progres has occurred in this field.
3.1. Endocrine Therapy
Treating BC by hormonal deprivation is an historical observation dating back to 1896, when
Beatson described a new treatment strategy for inoperable breast carcinoma by ovaries removal [52].
Since then, a wide range of drugs have been developed with the aim of inhibit the estrogen signaling
pathway and treat the hormone receptor (HR) positive breast tumors. Three different categories of
endocrine treatment are now available:
• SE l ctive estrogen r ceptor modulators): they are comp titive partial agonists of the
estrogen receptor. Particularly, tamoxifen is the oldest and the most well-known dru of this
category [53]. Subseque tly, toremifene citrate was developed with the goal of achieving efficacy
similar to that of tamoxifen and with an improved saf ty profil . To date, al hough studies
have not confirmed a better safety profile, clinical data have supported th efficacy and of
tore ifene for the treatment of BC in postmenopausal patients [54].
• Aro atase Inhibitors: t e st t e r cti f estro e in post eno a sal o e by
inhibiting the activity of aromatase. e t ir - e erati ar atase i i it rs a e largely
replaced ta oxifen in the treatment of postmenopausal HR positive BC patients. The are
classified into irreversible steroidal inhibitors, such as exe estane, that for a per anent and
deactivating bond ith the aro atase enzy e, and non-steroidal inhibitors, such as anastrozole
and letrozole, that act via reversible competition for the aromatase enzyme [55–57].
• SERDs (selective estrogen receptor down-regulators): they reduce ER α protein levels, as well
as block estrogen receptor activity degrading and destroying the estrogen receptor. The only
approved SERD for the treatment of metastatic HR positive BC is fulvestrant [58,59].
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3.2. Anti-HER Agents
Since the development of the first anti-HER2 agent, the prognosis of patients with HER2 positive
tumors, which represent the 20%–25% of all BC, has significantly improved [60,61]. In the following
years, several therapeutic strategies for the treatment of HER2 positive BC have been developed:
• Recombinant humanized monoclonal antibodies (trastuzumab and pertuzumab): binding
the extracellular domain of HER2, trastuzumab blocks the dimerization of HER2 while
pertuzumab inhibits the heterodimerization of HER2 with other HER receptors, inhibiting the
downstream signaling pathways (PI3K and MAPK) with a cytostatic mechanism; they also have a
cytotoxic mechanism through the activation of the antibody dependent cell-mediated cytotoxicity
(ADCC) [62–64].
• Antibody-drug conjugates (TDM1): it conjugates efficacy of trastuzumab with the cytotoxic effect
of DM1 (emtansine), a tubulin inhibitor [65,66].
• Receptor tyrosine kinase inhibitors (RTKIs) (lapatinib): they inhibit enzyme function of HER
family intracellularly, binding competitively to the intracellular kinase domain ATP-binding site
of EGFR and/or HER2 [67].
• Other anti-HER2 compounds are still under evaluation in clinical trials such as HER2 vaccines,
other monoclonal antibodies (such as ertumaxomab and margetuximab), and defucosylated
trastuzumab [11].
3.3. Compounds Targeting PI3K/AKT/mTOR Pathway
The protein kinases involved in this pathway are attractive and promising drug targets for BC
treatment, especially in endocrine and anti-HER2 resistance settings [68]. Several molecules have
already been investigated and showed interesting results in clinical trials:
AKT phosphorylation inhibitors. MK2206, ridaforolimus, perifosine, and others are currently
under evaluation in phase II clinical trials [69,70].
mTOR inhibitors. On the basis of BOLERO2 trial [71], in 2012 everolimus has been approved by
the Food and Drug Administration (FDA) for the treatment of postmenopausal women with advanced
HR positive, HER2 negative BC in combination with exemestane, after failure of treatment with
letrozole or anastrozole. Moreover, everolimus has also been studied in association to chemotherapy
and trastuzumab in the HER2 positive setting [72,73].
PI3Kα-selective inhibitors (alpelisib), PI3Kα/δ-selective inhibitors (pictilisib), PanPI3K inhibitors
(buparlisib). The first results of the phase III BELLE2 trial showed that the association of buparlisib to
fulvestrant is able to improve progression free survival (PFS) compared to fulvestrant alone in patients
with locally advanced or metastatic HR positive BC resistant to aromatase inhibitors [74]. On the
other hand, the FERGI and the PEGGY phase II trials failed in showing any significant clinical benefit
from adding pictilisib to either fulvestrant or paclitaxel in patients with HER2 negative, HR positive
BC [75,76]. Finally, a phase II trial showed that the combination of taselisib plus fulvestrant had an
acceptable side effect profile and clinical activity in patients with HER2 negative, HR positive advanced
BC [77].
3.4. Farnesyl Transferase Inhibitors
Farnesyl transferase (FTase) inhibitors are a class of antineoplastic agents developed to specifically
inhibit RAS signaling pathway. Particularly, Tipifarnib is a non-peptidomimetic, orally-bioavailable,
competitive inhibitor of FTPase that has already shown an activity in preclinical models and in phase I
and II studies in association to chemotherapy and endocrine therapy [78–80].
3.5. Anti-RTKs (FGFR, MET, and IGF-1R)
Several tyrosine kinase inhibitors (TKi) and monoclonal antibodies targeting single or multiple
RTKs have been studied:
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The anti-FGFR1 dovitinib has shown antitumor activity in advanced BC with FGF pathway
alterations, suggesting that FGFR could be a therapeutic target in these patients that warrants further
investigation [81]. Moreover, other FGFR inhibitors are currently under investigation in phase I/II
trials, such as luvitanib and nintedanib.
In a recent phase II study, the anti-MET tivantinib did not meet pre-specified statistical targets
for efficacy in triple-negative BC patients [82]. On the other hand, in heavily pretreated metastatic
BC patients, the anti-MET multi-targeted TK inhibitor cabozantinib demonstrated clinical activity,
including objective response and disease control [83]. Several other anti-MET compounds are still
under investigation in phase II clinical trials, such as foretinib and onartuzumab.
Finally, several IGF-1R inhibitors have been tested in clinical trials but, to date, have failed to
show any clinical benefit in unselected patients [84].
3.6. Cyclin-Dependent Kinase (CDK) Inhibitors
Palbociclib: the PALOMA1 phase II study revealed an impressive improvement in PFS with
palbociclib combined to letrozole [85] thus, in February 2015, FDA approved palbociclib plus letrozole
for first line treatment in ER positive HER2 negative advanced or metastatic BC. These data of PFS
improvement were then confirmed in the PALOMA 2 phase III study [86]. Subsequently, on the
basis of the results of the PALOMA3 trial [87], FDA extended the approval of palbociclib to include
therapy in combination with fulvestrant for HR positive, HER negative advanced or metastatic BC
after progression during endocrine therapy.
Ribociclib: in the phase III MONALEESA2 study, ribociclib plus letrozole showed significantly
longer PFS than placebo plus letrozole in patients receiving initial systemic treatment for HR-positive,
HER2-negative advanced breast cancer, but with a significant increase in the rate of toxicity [88].
Moreover, the phase III MONALEESA3 is investigating ribociclib in combination with fulvestrant and
the phase III MONALEESA7 trial is evaluating ribociclib in combination with tamoxifen and goserelin
or a non-steroidal aromatase inhibitor and goserelin for the treatment of premenopausal women.
Abemaciclib: the phase II MONARCH1 trial, abemaciclib induced objective tumor responses as a
monotherapy in patients with refractory HR positive HER2 negative metastatic BC following multiple
prior therapies [89]. Moreover, the phase III MONARCH2 study is evaluating the combination of
fulvestrant plus abemaciclib and the phase III MONARCH3 study is evaluating anastrozole or letrozole
plus abemaciclib in first line treatment.
3.7. Angiogenesis Inhibitors
Strategies to inhibit angiogenesis include the use of bevacizumab, a monoclonal antibody targeting
VEGF-A, and tyrosine kinase inhibitors (TKIs) (such as sunitinib). These targeted agents have
been studied both as monotherapies and in combination with chemotherapeutics. Nevertheless, in
several studies including the E2100, AVADO, and RIBBON-1 studies, the combination of angiogenesis
inhibitors with standard chemotherapy regimens in metastatic BC has resulted in improvement in PFS,
but not in overall survival (OS), while TKIs have not shown any efficacy in BC treatment yet [90–94].
3.8. SFK Inhibitors
Targeting SRC family kinases (SFKs) has the ability to inhibit different steps of carcinogenesis.
Dasatinib and other antineoplastic agents of this category are ATP-competitive inhibitors of SFKs, with
multiple effects still not fully understood [95,96]. Particularly, dasatinib is a tyrosine kinase inhibitor
that inhibits multiple oncogenic tyrosine kinases including SFKs, BCR-ABL, PDGF, and c-KIT and
that showed a role in osteoclast proliferation, survival, and resorptive function [97]. Nevertheless,
in a phase II trial, dasatinib did not demonstrate any effectiveness in controlling bone-predominant
metastatic BC in patients unselected by molecular biomarkers [98].
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3.9. HSP90 Function Inhibitors
HSP90 inhibitors have shown early promising results in defined molecular subgroups of solid
tumors, such as the HER2-positive BC [99], and are now under investigation in several clinical trials.
To date, promising results have been observed with tanespimycin in combination with trastuzumab in
patients progressing on trastuzumab [100] and, with single agent ganetespib in HER2-positive tumors
and TNBC [101].
3.10. PARP Inhibitors
PARP inhibitors exploit the synthetic lethality concept to prevent the DNA damage repair in
cells with homologous recombination deficiency, causing cancer cell death. Clinical evidence of
PARP inhibitors efficacy was initially slowed by negative results from a phase III trial of iniparib, a
compound at first classified as a PARP inhibitor [102]. After it was shown that iniparib does not inhibit
PARP in intact cells, clinical development of PARP inhibitors gained renewed interest. Currently,
five compounds are under investigation in clinical trials: olaparib in the phase III OlimpiA and
OlimpiAD studies, veliparib in the phase II BROCADE study and two phase III studies, niraparib in
the phase III BRAVO study, talazoparib in two phase II studies, and the phase III EMBRACA study and
rucaparib in two phase II studies [103–105]. Notably, based on the high sensitivity of BRCA-deficient
cells to PARP inhibitors, BRCA-mutation carriers are the most appropriate candidates for treatment
with PARP inhibitors.
3.11. Immunotherapy
Agonists of co-stimulatory receptors or antagonists of inhibitory receptors might lead to an
amplification of antigen-specific T cell response against tumor cells [106]. On these bases, multiple
immunotherapy approaches are under investigation in patients with BC: vaccines that elicit strong
specific immune responses to tumor antigens, such as WT-1 [107], HER2 [108], and NY-ESO-1 [109];
strategies involving adoptive transfer of in vitro-expanded, naturally-arising, or genetically-engineered
tumor-specific lymphocytes; therapeutic administration of monoclonal antibodies to target tumor cells;
approaches that inhibit the molecular or cellular mediators of cancer-induced immunosuppression,
such as CTLA-4 and PD-1 [50]. Particularly, the recent phase Ib KEYNOTE-012 trial demonstrated
that the PD-1 inhibitor pembrolizumab has activity and an acceptable toxicity profile as single-agent
therapy in heavily pretreated, advanced triple-negative BC [110]. Other clinical trials are currently
evaluating nivolumab (anti-PD1), ipilimumab (anti-CTLA-4), atezolizumab (anti-PD-L1), durvalumab
(anti-PD-L1), and tremelimumab (anti-CTLA-4) in BC patients.
4. Resistance Mechanisms to Targeted Therapies
The incoming resistance to targeted therapies is a major limitation to treatment efficacy. Primary
or intrinsic resistance occurs when an inherent feature of the cancer cells prevents the drugs from
working. On the other hand, secondary, or acquired, resistance occurs when cancer cells become
resistant during treatment and it manifests over time after an initial response [111].
BC behaves as an evolving entity, with metastases acquiring different biological profiles as
compared to their matched primary tumors [112,113]. A large body of evidence indicated relevant rates
of discordance between primary tumor and subsequent metastatic disease [114,115]. This biological
evolution is exacerbated by the selective pressure imposed by treatments during the natural history
of the disease, thus modifying its sensitivity or resistance to therapies. On these bases, the
importance of molecular re-characterization of metastatic BC has become central in the management
of the disease and it has been recently acknowledged in the clinical recommendations of principal
international guidelines.
In HR positive BC, multiple mechanisms of endocrine resistance have been described, including
mutations in ESR1 gene which encode ERα. Particularly, mutations in ESR1 appear to be rare
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in treatment naive setting and more frequent in advanced BC previously treated with aromatase
inhibitors [116]. Other mechanisms of endocrine resistance are: up regulation of alternative crosstalk
signaling pathways, altered expression of specific microRNAs, balance of co-regulatory proteins, and
genetic polymorphisms involved in endocrine therapy metabolic activity [16]. Interestingly, some of
these mechanisms have been exploited with the aim to find strategies able to overcome endocrine
treatment resistance:
Hyperactivation of PI3K/AKT/mTOR pathway through mutations/amplifications affecting the
genes encoding the PI3K catalytic subunits (PIK3CA, PIK3CB), PI3K regulatory subunit (PIK3R1),
receptor tyrosine kinases (HER2, FGFR1), K-Ras, PI3K effectors (AKT1, AKT2, PDK1), and loss of
PTEN and INPP4B [117]. On these bases, the mTOR inhibitor everolimus has already been approved
for advanced HR positive, HER2 negative BC in combination with exemestane and, several other
inhibitors of this pathway in association to endocrine therapy are under evaluation.
Dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs),
and particularly CDK4/6 (through the CCND1 amplification, CDK4 amplification, loss of CDKN1B,
CDKN2A, and CDKN2B, RB1 mutation) [118]. On these bases, the CDK4/6 inhibitors palbociclib
and ribociclib have been investigated in association to endocrine therapy and are now entering
clinical practice.
Epigenetic aberrations through the methylation of specific DNA genes (such as RASSF1A, CCND2,
GSTP1, and TWIST) that are able to alter the expression of ER. On this basis, histone deacetylase
(HDAC) inhibitors have been investigated and showed the capability of partially restoring ER
expression. Particularly, entinostat demonstrated to restore sensitivity to hormonal therapy and
to improve PFS and OS when given in combination with exemestane, in patients with ER-positive
advanced BC resistant to previous aromatase inhibitors [119].
In HER2 positive BC, the main mechanisms of resistance to anti-HER2 agents include: impaired
access to HER2 by expression of extracellular domain-truncated HER2 (p95 HER2); overexpression
of Mucin 4, a mucin protein encoded by the MUC4 gene that serves as a ligand for HER2;
alternative signaling from other RTKs, such as IGF-1R, other HER family members, or MET;
loss of downstream controllers (PTEN, p27); and activation of downstream signaling pathways
(PI3K/AKT/mTOR and MAPK pathways) [11,120]. The main strategies developed to overcome
resistance in trastuzumab-refractory HER2-positive tumors are: TKIs (lapatinib), antibody-drug
conjugates (TDM-1), dual inhibition of HER2 (pertuzumab + trastuzumab, lapatinib + trastuzumab),
HER2 vaccines, other monoclonal antibodies (margetuximab and ertumaxomab), and defucosylated
trastuzumab. Furthermore, since the activation of growth factor receptors (such as IGF-1R,
HER, and MET) and ER activate crosstalking downstream signaling pathways, particularly the
PI3K/AKT/mTOR and MAPK pathways, some of the strategies developed in order to overcome
anti-HER2 treatment resistance overlap to those developed for endocrine-resistant disease. Particularly,
PI3K/AKT/mTOR pathway inhibitors, inhibitors of alternative signaling molecules (IGF-1R, FGFR
and MET) and HSP90 inhibitors have been evaluated in trastuzumab-refractory HER2-positive tumors.
5. Predictive Molecular Biomarkers
Currently, several molecularly targeted drugs are available in clinical practice or in the context
of clinical trials and, nowadays, with the aim to personalize treatment strategies, the challenge is
mainly represented by the optimal selection of the most effective treatment for each patient. On these
bases, parallel to the development of new therapeutic strategies, researchers are looking for molecular
biomarkers able to predict response to those treatments. For some of these targeted therapies, predictive
biomarkers have already been identified in clinical trials and are described below and in Table 1.
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Table 1. Molecular biomarkers predictive of response to targeted treatment in clinical trials.
Molecular Biomarkers Method of Analysis Targeted Therapy References
ESR1 mutations
ctDNA sensitivity to FULVESTRANT Fribbens 2016; [121]
ctDNA resistance to EXEMESTANE Fribbens 2016; [121]
Y537S mutation
in ctDNA resistance to EVEROLIMUS Chandarlapaty 2016; [122]
PIK3CA mutations
Tumor tissue sensitivity to EVEROLIMUS André 2016; [123]
ctDNA sensitivity to BUPARLISIB Baselga 2015; [74]
Tumor tissue sensitivity to TASELISIB Dickler 2016; [89]
Tumor tissue resistance to LAPATINIB Baselga 2016; [124]
AKT1 mutations Tumor tissue sensitivity to EVEROLIMUS André 2016; [123]
mTORC1 activation
(high p4EBP1, low 4EBP1,
low liver kinase B1, low
pAkt, and low PI3K)
Tumor tissue sensitivity to EVEROLIMUS Treilleux 2015; [125]
FGF pathway amplified Tumor tissue sensitivity to DOVITINIB André 2013; [81]
HER2 amplification
Tumor tissue sensitivity to TRASTUZUMAB Dawood 2010; [60]
Serum samples and
tumor tissue sensitivity to PERTUZUMAB Baselga 2014; [64]
Tumor tissue sensitivity to LAPATINIB Baselga 2016; [124]
Tumor tissue sensitivity to TDM1 Baselga 2016; [124]
EGFR down expression Tumor tissue sensitivity to TDM1 Baselga 2016; [124]
HER3 down expression Tumor tissue sensitivity to TDM1 Baselga 2016; [124]
VEGF-A and VEGFR-2
high concentration Serum samples sensitivity to BEVACIZUMAB Miles 2013; [126]
Low PTEN concentration Tumor tissue
sensitivity to EVEROLIMUS Jerusalem 2013; [127]André 2016; [123]
sensitivity to TDM1 Baselga 2016; [124]
High pS6 concentration Tumor tissue sensitivity to EVEROLIMUS Jerusalem 2013; [127]
Hyperacetylation of lysines Serum samples sensitivity to ENTINOSTAT Yardley 2013; [119]
5.1. Fulvestrant
A recent prospective-retrospective analysis evaluated circulating tumor DNA (ctDNA) in archived
baseline plasma from the SoFEA trial in order to assess the impact of ESR1 mutation on the efficacy
of fulvestrant and examestane. ctDNA is tumor-related circulating free DNA released in the blood
by tumor cells in necrosis and represents a promising biomarker for non-invasive assessment of
tumor DNA. Patients with ESR1 mutations in ctDNA had improved PFS after taking fulvestrant
compared with exemestane, whereas patients with wild-type ESR1 had similar PFS after receiving
either treatment. In this analysis, the detection of ESR1 mutations in plasma DNA predicted relative
resistance to exemestane and relative sensitivity to fulvestrant [121].
5.2. Everolimus
A retrospective exploratory biomarkers analysis of the BOLERO2 trial found that PFS benefit
with everolimus was maintained regardless of alteration status of PIK3CA, FGFR1, and CCND1,
or the pathways of which they are components [128]. An additional analysis studying the ctDNA
suggested that patients with PIK3CA activating mutations obtain a similar PFS benefit from everolimus
compared to patients without PIK3CA mutations (PI3KCA WT 56.7% PFS 7.36 month HR 0.43; PI3KCA
mutant 43.3% PFS 6.9 HR 0.37) [129]. Overall, these analyses support the evidence that the efficacy
of everolimus is independent of PIK3CA mutational status. Additionally, an exploratory analysis of
the BOLERO3 trial showed greater benefit derived from the addition of everolimus in HER2 positive
BC patients with a low PTEN concentration than in those with a high PTEN concentration and in
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patients with a high pS6 concentration than in those with low pS6 concentration, while again PIK3CA
mutations did not seem to predict any benefit [127]. On the other hand, the combined analysis of
BOLERO1 and 3 showed a significant PFS benefit in patients with HER2 positive advanced BC having
tumors with with PIK3CA mutations, PTEN loss or hyperactive PI3K pathway (PIK3CA mutations
and/or PTEN loss and/or AKT1 mutation) treated with everolimus in combination with trastuzumab,
plus either paclitaxel or vinorelbine. On the contrary, an everolimus benefit was not seen in patients
with wild-type PIK3CA, normal PTEN, or normal PI3K pathway activity [123].
Another recent analysis of BOLERO2 evaluated the incidence of ERS1 mutation and its clinical
impact. The result of this analysis demonstrated that addition of everolimus was associated with
improved PFS for patients with wild-type or D538G mutation but not for those with Y537S mutation.
Overall, this analysis showed a potential lack of benefit in tumors with either the Y537S mutation alone
or with both Y537S and D538G [122].
Finally, an exploratory analysis of the TAMRAD study evaluated potential predictive markers of
everolimus efficacy using primary tumor samples obtained from enrolled patients. Particularly, the
analysis evaluated the proteins that result in mTORC1 activation, the PIK3CA gene and the KRAS
gene. The patients most likely to have an improvement in TTP with tamoxifen/everolimus therapy,
compared with tamoxifen alone, were those with high p4EBP1, low 4EBP1, low liver kinase B1, low
pAKT, and low PI3K [125].
5.3. Buparlisib
A sub-analysis of the BELLE2 study indicated that patients who had mutant PIK3CA detected in
their ctDNA had much better outcomes if they received buparlisib plus fulvestrant when compared
with those who received fulvestrant alone (HR 0.56; p-value < 0.001). This study suggests that the
research of mutational status of PI3KCA in ctDNA may help in the selection of patients who benefit
the most from adding a PI3K inhibitor to endocrine therapy [74].
Moreover, the BELLE-3 phase III trial is investigating the efficacy of buparlisib plus fulvestrant
in postmenopausal patients with HR+/HER2− advanced BC previously treated with an aromatase
inhibitor and refractory to mTOR inhibitor-based therapy. Also in this study, PFS, OS, ORR, and the
clinical benefit rate will be evaluated based on ctDNA PIK3CA mutation status [130].
5.4. Pictilisib
In the FERGI phase II trial, the PIK3CA mutation status was not associated to an improvement
in PFS or ORR with pictilisib [75]. In addition, also the PEGGY phase II trial failed in showing any
significant clinical benefit from adding pictilisib to paclitaxel in patients with advanced HER2 negative,
HR positive BC, in either the ITT population or the PIK3CA mutated subgroup [76].
5.5. Alpelisib and Taselisib
Two ongoing phase III trials are evaluating the use of PIK3CA mutation in ctDNA as a predictor
marker for a response to the α-specific PI3K inhibitor: SOLAR-1 and SANDIPIPER. The first trial
investigates the combination of alpelisib and fulvestrant, the patients are screened and stratified based
on PI3KCA mutation status and randomized to receive fulvestrant in combination with either alpelisib or
placebo [131,132]. The second study follows a phase II trial that showed how the combination of taselisib
plus fulvestrant had an acceptable side effect profile and clinical activity in patients with HER2 negative,
HR positive advanced BC, with a numerically higher response in patients with PIK3CA mutations [77].
SANDIPIPER studies the combination of taselisib plus fulvestrant in patients with ER positive, HER2
negative locally advanced or metastatic BC enriched for patients with PIK3CA mutant tumors [133].
5.6. Dovitinib
Dovitinib has already shown antitumor activity in FGFR-amplified BC cell lines in preclinical
models, and in a phase II trial recruiting patients with metastatic BC with and without FGFR1
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amplification, dovitinib showed increased activity in BC with FGF pathway amplification. Particularly,
dovitinib showed more potent antitumor activity in patients with FGF pathway-amplified BC
(amplifications in FGFR1, FGFR2, or FGF3) [81]. On these bases, dovitinib is under evaluation in
combination with fulvestrant in a phase II randomized trial in patients with BC who have FGF-pathway
amplifications (FGFR1, FGFR2, or FGF3) [134].
5.7. Trastuzumab
HER2 overexpression is predictive for anti-HER2 therapy and its research is already routine in
clinical practice [60,135].
5.8. Pertuzumab
In the CLEOPATRA trial, pertuzumab in association to trastuzumab and docetaxel showed to
improve PFS and OS in the first line treatment of HER2 positive metastatic BC. Baselga et al. performed
a biomarker analysis of tumor samples from patients in CLEOPATRA but, similarly to prior studies,
identified prognostic and no predictive markers. Particularly, high HER2 protein, high HER2 and
HER3 mRNA levels, wild-type PIK3CA and low serum HER extracellular domain were associated
with a significantly better prognosis [64]. At the moment HER2 remain the only marker suited for
patient selection for trastuzumab plus pertuzumab-based regimen in HER2 positive metastatic BC.
5.9. LAPATINIB and TDM-1
Lapatinib has been the only HER2 target agent available for trastuzumab resistant patients, until
the superiority of TDM-1 over lapatinib and capecitabine was demonstrated by the results of the
EMILIA trial in 2012. In a sub analysis of the EMILIA trial, tumors tissues were evaluated for HER2,
EGFR, and HER3 mRNA expression by quantitative reverse transcriptase PCR, for PTEN protein
expression by IHC, and for PIK3CA mutations using a mutation detection kit. The presence of PIK3CA
mutations was associated with shorter PFS and OS durations in patients who received lapatinib, but
did not adversely affect efficacy with T-DM1. Moreover, T-DM1 appeared to result in a greater PFS
benefit versus lapatinib also in patients with absent or decreased PTEN expression. Additionally,
consistently with previous reports [136–138], the authors observed that tumors with HER2 mRNA
over-expression (over the median level) were characterized by increased sensitivity to treatment with
either T-DM1 or lapatinib. On the other hand, the PFS and OS benefit with T-DM1 was greater in
patients with tumors expressing EGFR or HER3 mRNA below the median level [124]. These results
confirm the previous preclinical findings that loss of PTEN or activation of PIK3CA through hotspot
mutations (E545K in the HD in exon 9 and H1047R in KD exon 20) confer resistance to lapatinib in
HER2 overexpressing BC cells [139].
5.10. Neratinib
Approximately 1.6% of all newly-diagnosed BC may harbor a HER2 mutation, and most of these
patients do not have HER2 gene amplification or overexpression. This percentage might be even
higher for patients who have relapsed. These HER2 somatic mutations are an alternative mechanism
to activate HER2 in BC. HER2 mutation positive patients represent a subpopulation that likely benefits
from HER2-targeted drugs, particularly irreversible inhibitors such as neratinib. Interestingly, in
preclinical models all the 13 functionally characterized mutations were sensitive to neratinib, including
those that cause resistance to lapatinib [140,141]. The preliminary analysis from the SUMMIT phase
II study demonstrated encouraging sign of clinical activity of neratinib in patients with heavily
pre-treated, HER2 mutant, HER2 non-amplified metastatic BC [142].
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5.11. Palbociclib
An exploratory analysis of the PALOMA1 trial revealed no additional predictive value of CCND1
amplification or p16 loss for palbociclib efficacy [85,143]. Moreover, in the PALOMA3 study PIK3CA
status in cfDNA did not show to significantly affect neither the magnitude of benefit associated with
fulvestrant plus palbociclib nor the hormone-receptor status of BC [87].
A recent prospective retrospective analysis performed ctDNA analysis in archived baseline plasma
from SoFEA and PALOMA3 trials in order to assess the impact of ESR1 mutation on the efficacy of
current therapies. In the PALOMA3 trial, ESR1 mutations were associated with acquired resistance to
prior aromatase inhibitors. Nevertheless, fulvestrant plus palbociclib improved PFS compared with
fulvestrant plus placebo in both ESR1 mutant and ESR1 wild-type patients [121].
5.12. Bevacizumab
The AVADO trial showed that high baseline plasma VEGF-A and VEGFR-2 concentrations were
associated with greater PFS benefit from bevacizumab [126].
5.13. Entinostat
The phase II Encore 301 study showed that the addition of the HDAC inhibitor entinostat to
exemestane improve PFS and OS in patients with advanced ER positive BC failing an aromatase
inhibitor [119]. The biomarker analysis showed that patients who presented hyperacetylation of
lysines induced by HDAC inhibitors in blood samples had a reduced risk of disease progression.
An ongoing confirmatory phase III trial E2112 will better define the role of HDAC inhibitors and
confirm the change in protein lysine acetylation as biomarker of response [144].
5.14. Parp-Inhibitors
Predictive biomarkers of response to PARP inhibitors have yet to be identified. A candidate
biomarker is the combination of three DNA-based homologous recombination deficiency (HRD) scores.
These HRD scores highly correlated with defects in BRCA1/2, and are associated with a response to
platinum therapy in triple-negative BC [145]. The value of an HRD score in predicting a response to
PARP inhibitors is currently under evaluation in prospective studies with advanced BC patients.
5.15. Immunotherapy
PD-L1 expression on tumor cells may not be considered a definitive predictive biomarker for the
response to PD-1/PD-L1 blockade, since in some tumors the response to PD-1/PD-L1 blockades is
independent of PD-L1 expression [146]. On the other hand, PD-L1 expression seems to correlate with the
presence of tumor-infiltrating lymphocytes (TILs) and TILs showed to possess the possibility to predict
the response of checkpoint blockades in 41 patients with melanoma, non-small cell lung carcinoma, renal
cell carcinoma, colorectal carcinoma, or castration-resistant prostate cancer [147]. Nonetheless, further
research is needed to accurately identify patients who will benefit from checkpoint blockades.
6. Conclusions
Recent evidence emerging from clinical trials provided demonstrations that the genetic landscape
of any given tumor is able to dictate its sensitivity or resistance profile to matched anticancer agents and
some studies have already showed that in patients receiving therapies matched with their molecular
alterations, the objective response rate may be higher and the PFS and survival may be longer [148–150].
Nevertheless, these results are still widely debated [151] and, to date, very few predictive molecular
biomarkers have been identified for the treatment decision-making in metastatic BC patients.
A promising field of research for the detection of predictive biomarkers is represented by the study
of microRNA (miRNA). The miRNAs are endogenous, small non-coding RNA molecules that showed
an aberrant expression in breast cancer patients [152]. Particularly, miRNA dysregulation, in either
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cancer tissues or plasma, may predict a patient’s response to treatments. For instance, up-regulated
miR-210 in tissues has been associated with higher risk of recurrence in tamoxifen-treated patients [153],
while increased levels of miR-210 in the plasma were correlated with trastuzumab resistance [154].
However, the study of miRNA requires further research and an optimization of detection strategies,
therefore, to date, this approach has not yet been introduced in clinical practice.
In the era of personalized medicine, future research should be directed into two parallel directions.
On the one hand, the increasing knowledge on cancer signaling pathways should encourage the
identification of new molecular targets for the development of anti-cancer agents that are likely to
improve treatment response and circumvent resistance. On the other hand, more translational research
is required to identify biomarkers that could help to predict response and resistance, in order to
improve the selection of the optimal targeted treatment for each patient.
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